From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiacmuscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal musclemyosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca 2+ release .
3-Chlorodiphenylamine is a high affinity Ca 2+ sensitizer of cardiacmuscle. 3-Chlorodiphenylamine is based on diphenylamine and binds to the isolated N-domain of cardiac troponin C (cTnC) (Kd=6 µM). 3-Chlorodiphenylamine is an excellent starting scaffold for the development of more potent Ca 2+-sensitizing compounds due to its small size, and can be used for systolic heart failure research .
Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiacmuscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiacmuscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .
RS-87337 is an orally active antiarrhythmic agent that increases the duration and the maximum rate of rise of cardiacmuscle action potentials. RS-87337 is promising for research of antiarrhythmic and cardioprotective agents .
Human cardiac troponin (mixture) (cTn) is a regulatory protein for muscle tissue contraction, located on the thin filaments of contractile proteins, and plays an important regulatory role in muscle contraction and relaxation .
JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiacmuscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy .
Doxorubicinol, a potent inhibitor of the cardiac sarcoplasmic reticulum calcium pump, inhibits systolic myocardial function in isolated heart muscle. Doxorubicinol inhibits tumor cell growth and has cardiotoxicity.
Disopyramide hydrochloride is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide hydrochloride blocks the fast inward sodium current of cardiacmuscle and prolongs the duration of cardiac action potentials. Disopyramide hydrochloride inhibits HERG encoded potassium channels. Disopyramide hydrochloride also exhibits complex protein binding, and has a potent negative inotropic action .
Etamiphyllin camsylate (Etamiphylline camsylate) is a cardiac stimulant with oral activity that increases cardiac output without increasing heart rate. Etamiphyllin camsylate is also a respiratory stimulant used for respiratory failure, as Etamiphyllin camsylate relaxes the smooth muscles of the bronchi and bronchioles, thereby opening up the airways to relieve chronic obstructive pulmonary disease .
Troponin modulator 1 (compound 7) modulates the mutant cardiacmuscle thin filament function. Troponin modulator 1 enhances Ca 2+ sensitivity by phosphorylation with an EC50 of 67 μM .
JB061 is a nonmuscle myosin inhibitor with IC50s of 4.4 μM (Cardiacmuscle myosin), 9.1 μM (Skeletal muscle myosin), and >100 μM (Smooth muscle myosin II), respectively. JB061 poorly decreases ATPase activity (IC50>200 μM). JB061 shows cytotoxicity against COS-7 cells with an IC50 value of 39 μM .
Disopyramide (Standard) is the analytical standard of Disopyramide. This product is intended for research and analytical applications. Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiacmuscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
Disopyramide (phosphate) (Standard) is the analytical standard of Disopyramide (phosphate). This product is intended for research and analytical applications. Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiacmuscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .
(+)-Sotalol ((S)-Sotalol) is the S-isomer of Sotalol (HY-103196). Sotalol is an orally active, non-selective β-adrenergic receptor blocker. (+)-Sotalol is an antiarrhythmic agent. (+)-Sotalol can prolong action potential duration in isolated cardiacmuscle .
1,4-Dihydropyridine is an inhibitor for calcium channel, that blocks the L-type calcium channels, reduces the influx of calcium ions into cardiac and vascular smooth muscle cells, and thus reduces the contractility and heart rate of the heart, dilates blood vessels, and lowers blood pressure .
AGL 2043 is an effective inhibitor of PDGFR (IC50=0.8 μM) and TEL-PDGFR kinases, as well as FLT3 and KIT kinases. AGL 2043 can effectively inhibit porcine cardiac smooth muscle cell proliferation and balloon-induced vascular stenosis, and is suitable for development as an anti-restenotic and anticancer agent .
MuRF1-IN-1 is an orally active MuRF1 inhibitor. MuRF1-IN-1 can inhibit the interaction between MuRF1 and titin as well as E3 ligase activity. MuRF1-IN-1 can alleviate skeletal muscle atrophy and dysfunction in cardiac cachexia .
Nifenalol hydrochloride is a β-adrenergic receptor antagonist. Nifenalol hydrochloride induces the Early Afterdepolarization (EAD) effect. EAD is a phenomenon in cardiac electrophysiology that usually occurs during an action potential in ventricular muscle cells and can lead to arrhythmia. The EAD effect of Nifenalol hydrochloride can be blocked by Tetrodotoxin. Nifenalol hydrochloride is used in the study of conditions such as irregular heartbeat or high blood pressure .
M617 is a selective galanin receptor 1 (GAL1) agonist, with Kis of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiacmuscle of type 2 diabetic rats .
M617 TFA is a selective galanin receptor 1 (GAL1) agonist, with Kis of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617 TFA, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiacmuscle of type 2 diabetic rats .
Etilefrine hydrochloride is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine hydrochloride stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine hydrochloride also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine hydrochloride also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine hydrochloride can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output .
Etilefrine is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output .
Etilefrine hydrochloride (Standard) is the analytical standard of Etilefrine hydrochloride (HY-A0144A). This product is intended for research and analytical applications. Etilefrine hydrochloride is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine hydrochloride stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine hydrochloride also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine hydrochloride also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine hydrochloride can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output .
ZD0947 is an ATP-sensitive potassium channel activator with relatively effective activation of smooth muscle KATP channels (SUR2B/Kir6.1 and SUR2B/Kir6.2). ZD0947 partially antagonizes pancreatic KATP channels (SUR1/Kir6.2) and cardiac KATP channels (SUR2A/Kir6.2). ZD0947 is potentially used to inhibit overactive bladder (OAB) .
Carbuterol (SKF 40383-A) hydrochloride is a selective β2-adrenergic receptor agonist that primarily targets bronchial smooth muscle, exhibiting significant bronchodilatory and anti-allergic activity. Carbuterol hydrochloride can directly inhibit the immunologically induced release of histamine and slow-reacting substance of anaphylaxis (SRS-A), thereby alleviating allergic responses. In addition, it exerts mild β1-mediated cardiac stimulation and is applicable to studies related to respiratory and immune-related diseases such as asthma and allergic disorders .
ALK5-IN-82 is a potent and selective inhibitor against activin receptor-like kinase 5 (ALK5) with an IC50 value of 9.1 nM. ALK5-IN-82 inhibits the protein expression of α-smooth muscle actin (α-SMA), collagen I and tissue inhibitor of metalloproteinase 1 (TIMP-1)/matrix metalloproteinase 13 (MMP-13) in transforming growth factor-β-induced human umbilical vein endothelial cells. ALK5-IN-82 is promising for research of cardiac fibrosis .
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
3-(3-Hydroxyphenyl)propionic acid (3HPPA) is an endothelium-dependent nitric oxide (NO) release promoter and endothelial nitric oxide synthase (eNOS) activator. 3-(3-Hydroxyphenyl)propionic acid activates eNOS to mediate vascular smooth muscle relaxation and enhances endothelial cell NO synthesis, inducing vasodilation and reducing peripheral vascular resistance. 3-(3-Hydroxyphenyl)propionic acid can dose-dependently reduce systolic and diastolic blood pressure in spontaneously hypertensive rats (SHR) without affecting cardiac contractility or heart rate. 3-(3-Hydroxyphenyl)propionic acid has antihypertensive and vascular protective effects and can be used in the prevention and treatment of cardiovascular diseases .
Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion.
MCE offers a unique collection of 161 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.
Etilefrine hydrochloride is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine hydrochloride stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine hydrochloride also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine hydrochloride also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine hydrochloride can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output .
Human cardiac troponin (mixture) (cTn) is a regulatory protein for muscle tissue contraction, located on the thin filaments of contractile proteins, and plays an important regulatory role in muscle contraction and relaxation .
Etilefrine hydrochloride (Standard) is the analytical standard of Etilefrine hydrochloride (HY-A0144A). This product is intended for research and analytical applications. Etilefrine hydrochloride is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine hydrochloride stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine hydrochloride also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine hydrochloride also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine hydrochloride can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output .
M617 TFA is a selective galanin receptor 1 (GAL1) agonist, with Kis of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617 TFA, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiacmuscle of type 2 diabetic rats .
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
DPc10 is a biological active peptide. (This is amino acids 2460 to 2495 fragment of cardiac ryanodine receptor (RyR2). RyR2 controls calcium release from the sarcoplasmic reticulum, which begins muscle contraction. Mutated RyR2 is associated to ventricular tachycardia (VT) and sudden death.)
Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
3-(3-Hydroxyphenyl)propionic acid (3HPPA) is an endothelium-dependent nitric oxide (NO) release promoter and endothelial nitric oxide synthase (eNOS) activator. 3-(3-Hydroxyphenyl)propionic acid activates eNOS to mediate vascular smooth muscle relaxation and enhances endothelial cell NO synthesis, inducing vasodilation and reducing peripheral vascular resistance. 3-(3-Hydroxyphenyl)propionic acid can dose-dependently reduce systolic and diastolic blood pressure in spontaneously hypertensive rats (SHR) without affecting cardiac contractility or heart rate. 3-(3-Hydroxyphenyl)propionic acid has antihypertensive and vascular protective effects and can be used in the prevention and treatment of cardiovascular diseases .
Doxorubicinol, a potent inhibitor of the cardiac sarcoplasmic reticulum calcium pump, inhibits systolic myocardial function in isolated heart muscle. Doxorubicinol inhibits tumor cell growth and has cardiotoxicity.
Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
Cardiac troponin I, also known as Tnni3, plays a key role as an inhibitory subunit in the troponin complex, a key regulator of calcium sensitivity in actomyosin ATPase activity in striated muscle.Tnni3 interacts with TRIM63, emphasizing its involvement in complex cellular processes.Cardiac troponin I/Tnni3 Protein, Mouse (His-SUMO) is the recombinant mouse-derived Cardiac troponin I/Tnni3 protein, expressed by E.coli , with N-SUMO, N-6*His labeled tag.
C protein cardiacmuscle isoform; C-protein; cardiacmuscle isoform; cardiac MyBP C; cardiac MyBP-C; cardiac myosin binding protein C ; cardiac-type; CMH4; FHC; MYBP C; MYBPC; MYBPC3; Myosin binding protein C cardiac; Myosin binding protein C cardiac-type; Myosin-binding protein C; myosin-binding protein C cardiac type; MYPC3_HUMAN
MYBPC3 Protein, positioned in the crossbridge region of vertebrate striated muscle A bands, binds to myosin heavy chain (MHC), F-actin, and native thin filaments, influencing actin-activated myosin ATPase. Its presence suggests potential modulation of muscle contraction, indicating a functional impact on the contractile apparatus, or a structural role in muscle fibers. MYBPC3 Protein, Human (His-SUMO) is the recombinant human-derived MYBPC3 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.
C protein cardiacmuscle isoform; C-protein; cardiacmuscle isoform; cardiac MyBP C; cardiac MyBP-C; cardiac myosin binding protein C ; cardiac-type; CMH4; FHC; MYBP C; MYBPC; MYBPC3; Myosin binding protein C cardiac; Myosin binding protein C cardiac-type; Myosin-binding protein C; myosin-binding protein C cardiac type; MYPC3_HUMAN
MYBPC3 Protein, positioned in the crossbridge region of vertebrate striated muscle A bands, binds to myosin heavy chain (MHC), F-actin, and native thin filaments, influencing actin-activated myosin ATPase. Its presence suggests potential modulation of muscle contraction, indicating a functional impact on the contractile apparatus, or a structural role in muscle fibers. MYBPC3 Protein, Human (HEK293, His) is the recombinant human-derived MYBPC3 protein, expressed by HEK293 , with C-6*His labeled tag.
The ATP2A2 protein is a magnesium-dependent enzyme that hydrolyzes ATP and transfers calcium from the cytoplasm to the sarcoplasmic reticulum. It participates in autophagy during starvation and interacts with VMP1 to achieve ER isolating membrane contact. ATP2A2 Protein, Human (His) is the recombinant human-derived ATP2A2 protein, expressed by E. coli , with N-6*His labeled tag.
ATP5F1A is an important component of mitochondrial ATP synthase (complex V) that coordinates ATP production from ADP by utilizing the transmembrane proton gradient. As part of the F-type ATPase, the α and β subunits of ATP5F1A form the catalytic core to achieve ATP hydrolysis. ATP5F1A Protein, Human (His) is the recombinant human-derived ATP5F1A protein, expressed by E. coli , with N-6*His labeled tag.
ATP synthase alpha chain; ATP synthase alpha chain; mitochondrial; ATP synthase subunit alpha; ATP synthase subunit alpha mitochondrial; ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit 1; cardiacmuscle; ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit; 1; ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit; isoform 1; cardiacmuscle; ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit; isoform 2; non-cardiacmuscle-like 2; ATP sythase F1 ATPase; alpha subunit; ATP5A; Atp5a1; ATP5AL2; ATPA_HUMAN; ATPM; Epididymis secretory sperm binding protein Li 123m; hATP1; HEL-S-123m; MC5DN4; mitochondrial; Mitochondrial ATP synthetase; Mitochondrial ATP synthetase oligomycin resistant; Modifier of Min 2; Modifier of Min 2 mouse homolog; Modifier of Min 2; mouse; homolog of; MOM2; OMR; ORM; OTTHUMP00000163475
ATP5F1A is an important component of mitochondrial ATP synthase (complex V) that coordinates ATP production from ADP by utilizing the transmembrane proton gradient. As part of the F-type ATPase, the α and β subunits of ATP5F1A form the catalytic core to achieve ATP hydrolysis. ATP5F1A Protein, Human (His-SUMO) is the recombinant human-derived ATP5F1A protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.
troponin I type 3 (cardiac); cardiac troponin I; Troponin I, cardiacmuscle; Cardiomyopathy, familial hypertrophic, 7, included; CMD1FF; CMD2A; CMH7; cTnI; Familial hypertrophic cardiomyopathy 7; MGC116817; RCM1; Tn1; Tni; TNN I3; TNNC 1; TNNC-1; TNNC1; TNNI3; Troponin I cardiac; Troponin I cardiacmuscle; Troponin I cardiacmuscle isoform; Troponin I type 3 cardiac; troponin I, cardiac 3; TroponinI; Troponin I; TNNI3_HUMAN.
WB, IHC-P, ICC/IF, IP
Human
Cardiac Troponin I/TNNC1 Antibody is an unconjugated, approximately 23 kDa, rabbit-derived, anti-Cardiac Troponin I/TNNC1 monoclonal antibody. Cardiac Troponin I/TNNC1 Antibody can be used for:WB,IHC-P,ICC/IF,IP expriments in human background without labeling.
Myosin heavy chain Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 224 kDa, targeting to Myosin heavy chain. It can be used for WB,IHC-P,IF assays with tag free, in the background of Human, Mouse, Rat.
MYL2 Antibody (YA2709) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2709), targeting MYL2, with a predicted molecular weight of 19 kDa (observed band size: 19 kDa). MYL2 Antibody (YA2709) can be used for WB, IHC-P, IP experiment in human, mouse, rat background.
Cardiac Troponin T Antibody (YA2719) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2719), targeting Cardiac Troponin T, with a predicted molecular weight of 36 kDa (observed band size: 40 kDa). Cardiac Troponin T Antibody (YA2719) can be used for WB, IHC-P experiment in human, mouse, rat background.
MYH6; MYHC; MYHCA; MYHCB; Myosin heavy chain 6; Myosin heavy chain; Myosin-6; Myosin heavy chain; cardiacmuscle alpha isoform
WB, IHC-P
Human, Mouse, Rat
MYH6 Antibody (YA3200) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3200), targeting MYH6, with a predicted molecular weight of 224 kDa. MYH6 Antibody (YA3200) can be used for WB, IHC-P experiment in human, mouse, rat background.
alpha smooth muscle Actin Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 42 kDa, targeting to alpha smooth muscle Actin. It can be used for WB,IHC-P,FC,IP assays with tag free, in the background of Human, Mouse.
alpha smooth muscle Actin Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 42 kDa, targeting to alpha smooth muscle Actin. It can be used for WB, IF-Cell, IF-Tissue, IHC-P, FC, mIHC assays with tag free, in the background of Human, Mouse,Rat.
422 protein; cardiac Fatty Acid Binding Protein; FABP 11; FABP 3; FABP11; FABP3; FABPH_HUMAN; fatty acid binding protein 11; Fatty acid binding protein 3; Fatty acid binding protein 3 muscle and heart; Fatty acid binding protein 3 muscle and heart mammary derived growth inhibitor; Fatty acid binding protein 3 muscle; Fatty acid binding protein 3
ELISA
Human
FABP3 Antibody (YA968) is a mouse-derived non-conjugated IgG2b antibody (Clone NO.: YA968), targeting FABP3. FABP3 Antibody (YA968) can be used for ELISA experiment in human background.
422 protein; cardiac Fatty Acid Binding Protein; FABP 11; FABP 3; FABP11; FABP3; FABPH_HUMAN; fatty acid binding protein 11; Fatty acid binding protein 3; Fatty acid binding protein 3 muscle and heart; Fatty acid binding protein 3 muscle and heart mammary derived growth inhibitor; Fatty acid binding protein 3 muscle; Fatty acid binding protein 3
ELISA
Human
FABP3 Antibody (YA969) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA969), targeting FABP3. FABP3 Antibody (YA969) can be used for ELISA experiment in human background.
422 protein; cardiac Fatty Acid Binding Protein; FABP 11; FABP 3; FABP11; FABP3; FABPH_HUMAN; fatty acid binding protein 11; Fatty acid binding protein 3; Fatty acid binding protein 3 muscle and heart; Fatty acid binding protein 3 muscle and heart mammary derived growth inhibitor; Fatty acid binding protein 3 muscle; Fatty acid binding protein 3
WB, IHC-P
Human, Mouse, Rat
FABP3 Antibody (YA970) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA970), targeting FABP3, with a predicted molecular weight of 15 kDa (observed band size: 15 kDa). FABP3 Antibody (YA970) can be used for WB, IHC-P experiment in human, mouse, rat background.
